148 related articles for article (PubMed ID: 27855345)
1. Overexpression and enhanced specific activity of aldoketo reductases (AKR1B1 & AKR1B10) in human breast cancers.
Reddy KA; Kumar PU; Srinivasulu M; Triveni B; Sharada K; Ismail A; Reddy GB
Breast; 2017 Feb; 31():137-143. PubMed ID: 27855345
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of aldose reductase in human cancer tissues.
Saraswat M; Mrudula T; Kumar PU; Suneetha A; Rao Rao TS; Srinivasulu M; Reddy B
Med Sci Monit; 2006 Dec; 12(12):CR525-529. PubMed ID: 17136009
[TBL] [Abstract][Full Text] [Related]
3. Opposing roles of the aldo-keto reductases AKR1B1 and AKR1B10 in colorectal cancer.
Taskoparan B; Seza EG; Demirkol S; Tuncer S; Stefek M; Gure AO; Banerjee S
Cell Oncol (Dordr); 2017 Dec; 40(6):563-578. PubMed ID: 28929377
[TBL] [Abstract][Full Text] [Related]
4. Decreased levels of AKR1B1 and AKR1B10 in cancerous endometrium compared to adjacent non-cancerous tissue.
Hevir N; Sinkovec J; Lanišnik Rižner T
Chem Biol Interact; 2013 Feb; 202(1-3):226-33. PubMed ID: 23146748
[TBL] [Abstract][Full Text] [Related]
5. Aldo-keto reductase family 1 member B1 inhibitors: old drugs with new perspectives.
Liu J; Wen G; Cao D
Recent Pat Anticancer Drug Discov; 2009 Nov; 4(3):246-53. PubMed ID: 19522700
[TBL] [Abstract][Full Text] [Related]
6. Aldo-Keto Reductases as Early Biomarkers of Hepatocellular Carcinoma: A Comparison Between Animal Models and Human HCC.
Torres-Mena JE; Salazar-Villegas KN; Sánchez-Rodríguez R; López-Gabiño B; Del Pozo-Yauner L; Arellanes-Robledo J; Villa-Treviño S; Gutiérrez-Nava MA; Pérez-Carreón JI
Dig Dis Sci; 2018 Apr; 63(4):934-944. PubMed ID: 29383608
[TBL] [Abstract][Full Text] [Related]
7. Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members.
O'connor T; Ireland LS; Harrison DJ; Hayes JD
Biochem J; 1999 Oct; 343 Pt 2(Pt 2):487-504. PubMed ID: 10510318
[TBL] [Abstract][Full Text] [Related]
8. Inhibitor selectivity between aldo-keto reductase superfamily members AKR1B10 and AKR1B1: role of Trp112 (Trp111).
Zhang L; Zhang H; Zhao Y; Li Z; Chen S; Zhai J; Chen Y; Xie W; Wang Z; Li Q; Zheng X; Hu X
FEBS Lett; 2013 Nov; 587(22):3681-6. PubMed ID: 24100137
[TBL] [Abstract][Full Text] [Related]
9. Selectivity determinants of inhibitor binding to the tumour marker human aldose reductase-like protein (AKR1B10) discovered from molecular docking and database screening.
Zhao HT; Soda M; Endo S; Hara A; El-Kabbani O
Eur J Med Chem; 2010 Sep; 45(9):4354-7. PubMed ID: 20538382
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
Gallego O; Ruiz FX; Ardèvol A; Domínguez M; Alvarez R; de Lera AR; Rovira C; Farrés J; Fita I; Parés X
Proc Natl Acad Sci U S A; 2007 Dec; 104(52):20764-9. PubMed ID: 18087047
[TBL] [Abstract][Full Text] [Related]
11. AKR1B1 as a Prognostic Biomarker of High-Grade Serous Ovarian Cancer.
Hojnik M; Šuster NK; Smrkolj Š; Sisinger D; Grazio SF; Verdenik I; Rižner TL
Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159076
[TBL] [Abstract][Full Text] [Related]
12. STAR and AKR1B10 are down-regulated in high-grade endometrial cancer.
Sinreih M; Štupar S; Čemažar L; Verdenik I; Frković Grazio S; Smrkolj Š; Rižner TL
J Steroid Biochem Mol Biol; 2017 Jul; 171():43-53. PubMed ID: 28232277
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of AKR1B10 in nasopharyngeal carcinoma as a potential biomarker.
He YC; Shen Y; Cao Y; Tang FQ; Tian DF; Huang CF; Tao H; Zhou FL; Zhang B; Song L; He L; Lin LM; Lu FG; Liao DF; Cao D
Cancer Biomark; 2016; 16(1):127-35. PubMed ID: 26835713
[TBL] [Abstract][Full Text] [Related]
14. Expression of the Aldo-Ketoreductases AKR1B1 and AKR1B10 in Human Cancers.
Laffin B; Petrash JM
Front Pharmacol; 2012; 3():104. PubMed ID: 22685431
[TBL] [Abstract][Full Text] [Related]
15. AKR1B10 is induced by hyperglycaemia and lipopolysaccharide in patients with diabetic nephropathy.
Shaw N; Yang B; Millward A; Demaine A; Hodgkinson A
Cell Stress Chaperones; 2014 Mar; 19(2):281-7. PubMed ID: 23975544
[TBL] [Abstract][Full Text] [Related]
16. Selective inhibition of the tumor marker aldo-keto reductase family member 1B10 by oleanolic acid.
Takemura M; Endo S; Matsunaga T; Soda M; Zhao HT; El-Kabbani O; Tajima K; Iinuma M; Hara A
J Nat Prod; 2011 May; 74(5):1201-6. PubMed ID: 21561086
[TBL] [Abstract][Full Text] [Related]
17. [Downregulation of AKR1B10 gene expression in colorectal cancer].
Kropotova ES; Tychko RA; Zinov'eva OL; Zyrianova AF; Khankin SL; Cherkes VL; Aliev VA; Beresten' SF; Oparina NIu; Mashkova TD
Mol Biol (Mosk); 2010; 44(2):243-50. PubMed ID: 20586184
[TBL] [Abstract][Full Text] [Related]
18. Metabolomics reveals that aldose reductase activity due to AKR1B10 is upregulated in hepatitis C virus infection.
Semmo N; Weber T; Idle JR; Beyoğlu D
J Viral Hepat; 2015 Jul; 22(7):617-24. PubMed ID: 25487531
[TBL] [Abstract][Full Text] [Related]
19. AKR1B1 and AKR1B10 as Prognostic Biomarkers of Endometrioid Endometrial Carcinomas.
Hojnik M; Frković Grazio S; Verdenik I; Rižner TL
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298614
[TBL] [Abstract][Full Text] [Related]
20. Kinetic studies of AKR1B10, human aldose reductase-like protein: endogenous substrates and inhibition by steroids.
Endo S; Matsunaga T; Mamiya H; Ohta C; Soda M; Kitade Y; Tajima K; Zhao HT; El-Kabbani O; Hara A
Arch Biochem Biophys; 2009 Jul; 487(1):1-9. PubMed ID: 19464995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
